- The agreement allows CF patients aged ≥2yrs.with two copies of F508del mutation in CFTR gene to access Orkambi (lumacaftor/ivacaftor) and CF patients aged ≥12yrs. with either two or one copy of F508del mutation and copy of one of the other 14 licensed mutations to access Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor in England
- The collaboration also allows expanded access to Kalydeco (ivacaftor) in patients with R117H mutation aged ≥18mos. and with one of the nine licensed gating mutations aged≥ 12mos.
- The access agreement with NHS England is for all Vertex’s licensed CF therapies and any future indications of these therapies. Additionally, reimbursement agreement has been signed in Scotland, Australia and Spain
Click here to read full press release/ article | Ref: Vertex | Image: Investor Business Daily